Eli Lilly acquired preclinical-stage Engage Biologics for up to $202 million, including an undisclosed upfront and development milestone payments. Engage's Tethosome platform uses lipid nanoparticles to deliver a DNA transgene vector and an mRNA-encoded DNA-binding protein for sustained episomal expression, with preclinical focus on liver targets including hemophilia A and hepatocellular carcinoma.
Key facts
AnnouncedMay 20, 2026
ClosedMay 20, 2026
Deal value$202M
Deal typeAcquisition/Merger
Therapeutic areaGenetic medicines (liver-targeted; hemophilia A, hepatocellular carcinoma)
IndicationsGenetic medicines (liver-targeted; hemophilia A, hepatocellular carcinoma)
Key assetsTethosome non-viral DNA delivery platform
MechanismNon-viral LNP-based DNA + mRNA co-delivery for episomal expression